OPG-Fc Treatment in Growing Pigs Leads to Rapid Reductions in Bone Resorption Markers, Serum Calcium, and Bone Formation Markers

Abstract

Inhibition of the receptor activator of NF-κB ligand (RANKL) is a novel therapeutic option in the treatment of osteoporosis and related diseases. The aim of this study was to evaluate bone metabolism and structure in pigs after RANKL inhibition. 12 growing pigs were assigned to 2 groups with 6 animals each. The OPG group received recombinant human OPG-Fc (5 mg/kg IV) at day 0, the control group was given 0.9% NaCl solution. Serum levels of OPG-Fc, calcium (Ca), phosphorus (P), and bone turnover markers were evaluated every 5 days, and pigs were euthanized on day 20. Serum OPG-Fc concentration peaked at day 5 and coincided with significantly decreased Ca, P, and bone turnover markers. By day 15, measureable OPG-Fc serum levels could only be detected in 2/6 animals. With OPG-Fc clearance starting at day 10, serum Ca and P concentrations were not different between the 2 groups. TRACP5b, P1CP, and BAP levels significantly decreased by 40–70% relative to vehicle controls in the OPG-Fc group between days 5 and 10, indicating that pharmacologic concentration of OPG-Fc led to systemic concomitant inhibition of bone formation and resorption in young growing pigs. Dual X-ray absorptiometry data derived from the proximal femur did not differ between the 2 groups. μCT analysis of selected bone sites demonstrated an OPG-Fc-induced improvement of specific bone architectural indices and bone mineralization.

Key words

bone metabolism - RANKL inhibition - trabecular architecture

• References

• 1 Pietschmann P, Rauner M, Sipos W. Osteoporosis: an age-related and gender-specific disease – a mini-review. Gerontology 2008; 55: 3-12
• 2 Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009; 24: 182-185
• 3 Guidelines for Preclinical and Clinical Evaluation of Agents Used for the prevention or Treatment of Postmenopausal osteoporosis, Division of Metabolism and Endocrine Drug Products, U.S. Food and Drug Administration 1994
• 4 Sipos W, Pietschmann P, Rauner M. Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenesis in the fight against immune-mediated bone and joint diseases. Curr Med Chem 2008; 15: 127-136
• 5 Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S, Kostenuik PJ. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 2003; 18: 852-858
• 6 Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan HL, Corbin T, McCabe J, Simonet WS, Ke HZ, Kostenuik PJ. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res 2008; 23: 672-682
• 7 Sipos W, Duvigneau JC, Hofbauer G, Schmoll F, Baravalle G, Exel B, Hartl R, Dobretsberger M, Pietschmann P. Characterization of the cytokine pattern of porcine bone marrow-derived cells treated with 1α,25(OH)₂D₃ . J Vet Med A 2005; 52: 382-387
• 8 Sipos W, Kralicek E, Rauner M, Duvigneau JC, Worliczek HL, Schamall D, Hartl RT, Sommerfeld-Stur I, DallAra E, Varga P, Resch H, Schwendenwein I, Zysset P, Pietschmann P. Bone and cellular immune system of multiparous sows are insensitive to ovariectomy and nutritive calcium shortage. Horm Metab Res 2011; 43: 404-409
• 9 Allen MJ. Biochemical markers of bone metabolism in animals: uses and limitations. Vet Clin Pathol 2003; 32: 101-113
• 10 Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2: 595-610
• 11 Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765
• 12 Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139
• 13 Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000; 192: 463-474
• 14 Rodeo SA, Kawamura S, Ma B, Deng XH, Sussman PS, Hays P, Ying L. The effect of osteoclastic activity on tendon-to-bone healing: An experimental study in rabbits. J Bone Joint Surg 2007; 89: 2250-2259
• 15 Kim H, Morgan-Bagley S, Kostenuik PJ. RANKL inhibition: A novel strategy to decrease femoral head deformity after ischemic necrosis. J Bone Miner Res 2006; 21: 1946-1954
• 16 Ominsky MS, Kostenuik PJ, Cranmer P, Smith SY, Atkinson JE. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. Osteoporos Int 2007; 18: 1073-1082
• 17 Akatsu T, Murakami T, Ono K, Nishikawa M, Tsuda E, Mochizuki SI, Fujise N, Higashio K, Motoyoshi K, Yamamoto M, Nagata N. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 1998; 23: 495-498
• 18 Tomoyasu A, Goto M, Fujise N, Mochizuki SI, Yasuda H, Morinaga T, Tsuda E, Higashio K. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem Biophys Res Commun 1998; 245: 382-387
• 19 Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001; 16: 348-360
• 20 Cundy T, Davidson J, Rutland MD, Stewart C, DePaoli AM. Recombinant osteoprotegerin for juvenile Paget’s disease. N Engl J Med 2005; 353: 918-923
• 21 Burgess T, Qian YX, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999; 145: 527-538
• 22 Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000; 157: 435-448
• 23 Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, Kearns A, Thomas T, Boyd SK, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010; 25: 1886-1894
• 24 Mosekilde L, Weisbrode SE, Safron JA, Stills HF, Jankowsky ML, Ebert DC, Danielsen CC, Sogaard CH, Franks F, Stevens ML, Paddock CL, Boyce RW. Evaluation of the skeletal effects of combined mild dietary calcium restriction and ovariectomy in Sinclair S-1 minipigs: a pilot study. J Bone Miner Res 1993; 8: 1311-1321
• 25 Klopfenstein C, Farmer C, Martineau G-P. Diseases of the Mammary Gland. In: Straw BE, Zimmerman JJ, D’Allaire S, Taylor DJ. (eds) Diseases of Swine. Iowa: Blackwell Publishing; 2006: 57-86
• 26 Chang W, Tu C, Chen TH, Bikle D, Shoback D. The extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development. Sci Signal 2008; 1: 1
• 27 Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, Maasalu K, Bolognese MA, Woodson G, Bone H, Ding B, Wagman RB, San Martin J, Ominsky MS, Dempster DW. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010; 25: 2256-2265
• 28 Redd EH, Miller SC, Jee WS. Changes in endochondral bone elongation rates during pregnancy and lactation in rats. Calcif Tissue Int 1984; 36: 697-701
• 29 Miller SC, Shupe JG, Redd EH, Miller MA, Omura TH. Changes in bone mineral and bone formation rates during pregnancy and lactation in rats. Bone 1986; 7: 283-287
• 30 Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19: 1059-1066
• 31 Jin Q, Cirelli JA, Park CH, Sugai JV, Taba M, Kostenuik PJ, Giannobile WV. RANKL inhibition via osteoprotegerin blocks bone loss in experimental periodontitis. J Periodontol 2007; 78: 1300-1308
• 32 Pierroz DD, Bonnet N, Baldock PA, Ominsky MS, Stolina M, Kostenuik PJ, Ferrari SL. Are osteoclasts needed for the bone anabolic response to PTH? A study of intermittent PTH with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem 2010; 285: 28164-28173
• 33 Baron R, Ferrari S, Russel RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011; 48: 677-692